Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease

Nat Med. 2021 Feb;27(2):356. doi: 10.1038/s41591-021-01251-7.

Simon Dujardin^{1

2}, Caitlin Commins¹, Aurelien Lathuiliere^{1

2}, Pieter Beerepoot^{2

3}, Analiese R Fernandes¹, Tarun V Kamath¹, Mark B De Los Santos¹, Naomi Klickstein¹, Diana L Corjuc¹, Bianca T Corjuc¹, Patrick M Dooley^{1

4}, Arthur Viode^{2

3}, Derek H Oakley^{1

2

4}, Benjamin D Moore^{1

2

5}, Kristina Mullin⁶, Dinorah Jean-Gilles⁷, Ryan Clark⁷, Kevin Atchison⁷, Renee Moore⁷, Lori B Chibnik^{1

2

8}, Rudolph E Tanzi^{2

6}, Matthew P Frosch^{2

4}, Alberto Serrano-Pozo^{1

2}, Fiona Elwood^{7

9}, Judith A Steen^{2

3}, Matthew E Kennedy⁷, Bradley T Hyman^{10

11}

¹ Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
² Harvard Medical School, Boston, MA, USA.
³ F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.
⁴ C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, MA, USA.
⁵ Aquinnah Pharmaceuticals, Cambridge, MA, USA.
⁶ Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
⁷ Department of Neuroscience, Merck & Co., Boston, MA, USA.
⁸ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
⁹ Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
¹⁰ Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA. [email protected].
¹¹ Harvard Medical School, Boston, MA, USA. [email protected].

No abstract available

Publication types